MeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
MeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.51 per share a year ago.
Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know
MeiraGTx (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?
MeiraGTx (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity Transcript
MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity Transcript
MeiraGTx: Turning Dry Mouth Into Liquid Gold
MeiraGTx is approaching a pivotal Phase 1 data readout for AAV-hAQP1 in radiation-induced xerostomia, with the stock recently hitting 52-week highs. MGTX's riboswitch-controlled gene therapy platform, vertical integration, and big pharma partnerships differentiate its approach and support an ambitious pipeline. I estimate AAV2hAQP1's peak sales at ~$1.2B, with risk-adjusted NPV of $979.8M, and see tomorrow's data as a major de-risking event.
Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?
MeiraGTx (MGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
MeiraGTx Holdings plc (MGTX) Presents at RBC Capital Markets Virtual Ophthalmology Conference Transcript
MeiraGTx Holdings plc (MGTX) Presents at RBC Capital Markets Virtual Ophthalmology Conference Transcript
MeiraGTx Holdings PLC (MGTX) Q4 Earnings and Revenues Surpass Estimates
MeiraGTx Holdings PLC (MGTX) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of a loss of $0.6 per share. This compares to a loss of $0.5 per share a year ago.
MeiraGTx Holdings PLC (NASDAQ:MGTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of MeiraGTx Holdings PLC (NASDAQ: MGTX - Get Free Report) have received an average rating of "Moderate Buy" from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Lags Revenue Estimates
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.54 per share a year ago.
